Concerns and recommendations: antiplatelet agents and cancer prevention in non-alcoholic fatty liver disease.
作者信息
Pham Hong Tham, Truong-Nguyen Kim-Huong, Tran Minh-Hoang
机构信息
Faculty of Pharmacy, Nguyen Tat Thanh University, Ho Chi Minh, Vietnam.
Department of Pharmacy, Nhan Dan Gia Dinh Hospital, Ho Chi Minh, Vietnam.
出版信息
Front Oncol. 2025 Jul 14;15:1607955. doi: 10.3389/fonc.2025.1607955. eCollection 2025.
Abstract
摘要
相似文献
1
Concerns and recommendations: antiplatelet agents and cancer prevention in non-alcoholic fatty liver disease.关注与建议：非酒精性脂肪性肝病中的抗血小板药物与癌症预防
Front Oncol. 2025 Jul 14;15:1607955. doi: 10.3389/fonc.2025.1607955. eCollection 2025.
2
Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.用于非酒精性脂肪性肝病和非酒精性脂肪性肝炎的他汀类药物。
Cochrane Database Syst Rev. 2013 Dec 27;2013(12):CD008623. doi: 10.1002/14651858.CD008623.pub2.
3
The Evidence Surrounding Non-Alcoholic Fatty Liver Disease in Individuals with Cancer: A Systematic Literature Review.癌症患者非酒精性脂肪性肝病的证据：系统文献综述。
Curr Oncol. 2022 Dec 21;30(1):48-74. doi: 10.3390/curroncol30010005.
4
Antiplatelet therapy associated with lower prevalence of advanced liver fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.抗血小板治疗与非酒精性脂肪性肝病中晚期肝纤维化患病率较低相关：一项系统评价和荟萃分析。
Indian J Gastroenterol. 2022 Apr;41(2):119-126. doi: 10.1007/s12664-021-01230-3. Epub 2022 Mar 22.
5
Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?2型糖尿病合并非酒精性脂肪性肝病患者使用吡格列酮联合SGLT2抑制剂或GLP-1受体激动剂：老朋友与新药物联合使用能否产生更好的疗效？
Arch Med Sci Atheroscler Dis. 2025 Mar 14;10:e1-e15. doi: 10.5114/amsad/202298. eCollection 2025.
6
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.抗血小板和抗凝药物用于抗磷脂综合征患者中风和其他血栓栓塞事件的二级预防。
Cochrane Database Syst Rev. 2017 Oct 2;10(10):CD012169. doi: 10.1002/14651858.CD012169.pub2.
7
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.系统评价：成人非酒精性脂肪性肝病和非酒精性脂肪性肝炎的流行病学和自然史。
Aliment Pharmacol Ther. 2011 Aug;34(3):274-85. doi: 10.1111/j.1365-2036.2011.04724.x. Epub 2011 May 30.
8
Sex-specific effect of dietary fatty acids on non-alcoholic fatty liver disease.膳食脂肪酸对非酒精性脂肪性肝病的性别特异性影响。
Front Nutr. 2025 Jul 2;12:1582527. doi: 10.3389/fnut.2025.1582527. eCollection 2025.
9
Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.GLP-1 受体激动剂对非酒精性脂肪性肝病和非酒精性脂肪性肝炎肝纤维化程度和 CRP 的影响：系统评价和荟萃分析。
Prim Care Diabetes. 2024 Jun;18(3):268-276. doi: 10.1016/j.pcd.2024.03.005. Epub 2024 Mar 30.
10
Nonalcoholic fatty liver disease and hepatocellular carcinoma.非酒精性脂肪性肝病与肝细胞癌
Metabolism. 2016 Aug;65(8):1151-60. doi: 10.1016/j.metabol.2016.01.010. Epub 2016 Jan 23.
本文引用的文献
1
Cardiovascular Disease and Cancer: A Dangerous Liaison.心血管疾病与癌症：一种危险的关联。
Arterioscler Thromb Vasc Biol. 2025 Mar;45(3):359-371. doi: 10.1161/ATVBAHA.124.319863. Epub 2025 Jan 9.
2
The chemoprotective effect of anti-platelet agents on cancer incidence in people with non-alcoholic fatty liver disease (NAFLD): a retrospective cohort study.抗血小板药物对非酒精性脂肪性肝病（NAFLD）患者癌症发生率的化学保护作用：一项回顾性队列研究。
BMC Med. 2024 Dec 3;22(1):574. doi: 10.1186/s12916-024-03802-4.
3
Step-Based Dosing of Anticoagulants in COVID-19 Treatment.COVID-19治疗中抗凝剂的逐步给药法
Cureus. 2024 Aug 19;16(8):e67256. doi: 10.7759/cureus.67256. eCollection 2024 Aug.
4
Co-infections and secondary infections amid COVID-19 outbreaks in Vietnam.越南 COVID-19 疫情爆发期间的合并感染和继发感染。
BMC Infect Dis. 2024 Sep 9;24(1):945. doi: 10.1186/s12879-024-09866-0.
5
Comparison of the marginal hazard model and the sub-distribution hazard model for competing risks under an assumed copula.在假定的 copula 下，竞争风险的边际风险模型与子分布风险模型的比较。
Stat Methods Med Res. 2020 Aug;29(8):2307-2327. doi: 10.1177/0962280219892295. Epub 2019 Dec 22.
6
Should Patients With NAFLD/NASH Be Surveyed for HCC?非酒精性脂肪性肝病/非酒精性脂肪性肝炎患者应筛查肝细胞癌吗？
Transplantation. 2019 Jan;103(1):39-44. doi: 10.1097/TP.0000000000002361.
7
Immortal time bias in observational studies of time-to-event outcomes.事件发生时间结局观察性研究中的不朽时间偏倚。
J Crit Care. 2016 Dec;36:195-199. doi: 10.1016/j.jcrc.2016.07.017. Epub 2016 Jul 27.
8
Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care.当前误区 3：亚组特异性试验死亡率结果常常为个体化患者治疗提供了良好的基础。
Br J Cancer. 2011 Mar 29;104(7):1057-8. doi: 10.1038/bjc.2011.79.
9
Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods.药物有效性评估中与治疗开始时间相关的生存偏差：方法比较
Am J Epidemiol. 2005 Nov 15;162(10):1016-23. doi: 10.1093/aje/kwi307. Epub 2005 Sep 28.
10
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.17187例疑似急性心肌梗死患者静脉注射链激酶、口服阿司匹林、两者并用或两者均不用的随机试验：ISIS-2。ISIS-2（第二次心肌梗死存活国际研究）协作组
Lancet. 1988 Aug 13;2(8607):349-60.
Zotero 插件